Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28688451 | 0.78 | CYP2C9 (1.00) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL31261492 | 0.75 | CYP2C9 (0.76) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL2220566 | 0.74 | NPC1 (0.34) | CYP2C9KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL31054400 | 0.74 | CYP2C9 (0.69) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL2221815 | 0.74 | CYP2C9 (0.73) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL2266480 | 0.72 | CYP2C9 (0.32) | CYP2C9KMT2AMEN1 | |
| SCHEMBL13449431 | 0.70 | CYP2C9 (0.58) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL2269789 | 0.70 | CYP2C9 (0.58) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL359785 | 0.70 | KMT2A (0.71) | CYP2C9KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL13733791 | 0.70 | BAZ2B (0.36) | CYP2C9KMT2AMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | CYP2C9 4808/4885KMT2A 720/4885MEN1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.